Fachliteratur zur HPV-Impfung

Arbyn et al 2011: EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Brotherton et al 2011: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

Castellsagué et al 2012: Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study.

Dillner et al.2010: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Joura E. A., et al. 2015: A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Kjær et al 2010: Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Laprise J.-F., et al. 2016: Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis

Largeron N., et al. 2016: An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
 
Lehtinen et al.2012: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Machalek, Dorothy A., et al. 2018 Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18-to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. The Journal of infectious diseases

Moreira E. D., et al. 2016: Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials

Nielsen et al. 2010: Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women.

Paavonen et al. 2007: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Paavonen et al.2009: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Van Damme, Pierre, et al. 2016 Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine 34.6 (2016): 757-761.

Wheeler et al. 2012: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.